Skip to main content
. Author manuscript; available in PMC: 2015 Oct 16.
Published in final edited form as: Immunity. 2014 Oct 16;41(4):567–578. doi: 10.1016/j.immuni.2014.09.016

Fig. 4. RIPK3 protects against DSS-induced colitis through IL-22 expression.

Fig. 4

(A–B) Relative mRNA expression of (A) Il22 and (B) Reg3b in colon tissues of DSS-treated Ripk3+/+ (WT) and Ripk3−/− (KO) mice (day 7, n=5–12). (C) Body weight and (D) colon length on day 15 in the mice treated with 50 μg IL-22-Fc or isotype control IgG. The number in parentheses represents the number of mice used in each group. (E–F) Splenocytes were stimulated with IL-23 in the presence of PMA and Ionomycin. (E) IL-22 expression was determined by ELISA (n=4). (F) Representative FACS plots showing IL-22 expression in splenic ILCs (CD3−CD19−CD11b−IL-7R+CD4+CD25+ cells). The percentage of IL-22+ cells in splenic ILCs is shown on the right (n=4). Results shown are mean ± SEM. Asterisks: p < 0.05. See also Figure S4.